Table 5.

High-risk features to consider adjuvant systemic therapy (docetaxel/abiraterone)

STAMPEDE criteria	At least 2 of: T 3 or 4, PSA ≥ 40 ng/ml, Gleason 8–10 Stage pTany pN + M0
NRG Oncology/RTOG 0521 study criteria	Gleason 9–10 independent of PSA or T stage Gleason 7–8 and PSA ≥ 20 ng/ml with any T stage Gleason score 8 and PSA < 20 ng/ml with T stage ≥ T2